Results from the study were presented by principal investigator Dr. Nick Morrison of the Morrison Vein Institute in Scottsdale, Ariz., at the the European Venous Forum 2015 in St. Petersburg, Russia.
VenaSeal won approval from the FDA last February. Medtronic acquired the device when it paid $50 billion for Covidien in January. It uses a medical adhesive administered through a minimally invasive procedure that does not require tumescent anesthesia, Medtronic said.
“The VenaSeal closure system provides patients with a minimally invasive procedure that eliminates the need for surgery, thermal ablation and tumescent anesthesia. As a result, patients are often able to quickly return to normal activities after the procedure,” Morrison said in prepared remarks. “The results show sustained closure with VenaSeal closure system that is comparable to closure rates with radiofrequency at 12 months.”
The VeSeal study compared VenaSeal with another legacy Covidien product, the ClosureFast catheter, Medtronic said.
“The 12 month results of the VeClose trial demonstrates the durability of the system,” Medtronic aortic & peripheral vascular medical director Dr. Mark Turco added. “This, combined with the improved patient comfort and reduced recovery times of the VenaSeal closure system, makes this a clinically-proven, patient-friendly treatment option for patients.”